Pharmacology · Sedative-Hypnotic Drugs

Integrative Framework for Sedative-Hypnotic Pharmacology

Mechanism map, indication matching, and population-specific selection

All sedative-hypnotics converge on suppressing neuronal excitability — but through four distinct targets: GABA-A receptor enhancement (benzodiazepines, barbiturates, Z-drugs), melatonin receptor agonism (ramelteon), orexin receptor antagonism (suvorexant, lemborexant), or serotonin 5-HT1A partial agonism (buspirone).
The shift from barbiturates to benzodiazepines in the 1970s was driven by safety: the GABA-A ceiling effect of benzodiazepines dramatically reduced overdose lethality while preserving therapeutic efficacy.
The shift from benzodiazepines to newer agents continues for the same reason — Z-drugs and orexin antagonists carry lower dependence potential; ramelteon and buspirone carry essentially none.
CBT-I (cognitive behavioral therapy for insomnia) is more effective than pharmacotherapy for long-term outcomes and should be offered first for chronic insomnia; pharmacotherapy is appropriate short-term adjunctive treatment.
Three populations demand special consideration: the elderly (avoid benzodiazepines and barbiturates; prefer ramelteon or low-dose doxepin), patients with substance use disorders (avoid scheduled agents; prefer ramelteon or melatonin), and patients on opioids (the combination carries a boxed warning for synergistic respiratory depression).

Abbreviations: CBT-I = cognitive behavioral therapy for insomnia · 5-HT1A = serotonin 1A receptor · GABA = gamma-aminobutyric acid · ICD = impulse control disorder (not applicable here; see individual modules)

All-Class Mechanism Map

Drug Class	Molecular Target	Dependence	Key Differentiator
Benzodiazepines	GABA-A receptor — increase frequency of Cl− channel opening	Yes (Schedule IV)	Ceiling effect; reversible with flumazenil (with caveats)
Barbiturates	GABA-A receptor — increase duration of Cl− channel opening; direct activation at high doses	Yes (Schedule II–IV)	No ceiling effect; lethal in overdose; AMPA antagonism
Z-drugs	GABA-A receptor — relative alpha-1 subunit selectivity	Yes (Schedule IV)	Boxed warning: complex sleep behaviors
Ramelteon	Melatonin MT1/MT2 receptors	None (not scheduled)	Safest for elderly and substance-use history; small effect
Orexin antagonists	Dual orexin receptor antagonists — block wake signal	Low (Schedule IV)	Preserves sleep architecture; best for maintenance insomnia
Buspirone	Serotonin 5-HT1A partial agonist	None (not scheduled)	Anxiety only; no cross-tolerance with benzodiazepines

Clinical Niches: Who Gets What

Anxiety

First-Line Choices

Chronic GAD: SSRIs/SNRIs (first-line); buspirone (adjunct)
Panic disorder: clonazepam or alprazolam with SSRI bridge
Acute anxiety/procedures: benzodiazepines (short-term)
Avoid long-term benzodiazepines for anxiety (dependence, cognitive effects)

Insomnia

Agent-to-Complaint Matching

Onset only: zolpidem IR, zaleplon
Maintenance: orexin antagonists (suvorexant, lemborexant)
Onset and maintenance: eszopiclone or orexin antagonist
Comorbid depression: low-dose doxepin
Always offer CBT-I first for chronic insomnia

Seizures and Withdrawal

Emergency and Chronic Use

Status epilepticus: IV lorazepam → second-line antiseizure agent
Prehospital seizure: IM midazolam
Alcohol withdrawal: diazepam or chlordiazepoxide (CIWA-Ar guided)
Neonatal seizures: phenobarbital
Procedural sedation: midazolam (IV) or triazolam (oral premedication)

Population-Specific Selection

Population	Preferred	Avoid	Rationale
Elderly (>65)	Ramelteon; low-dose doxepin; orexin antagonists	Benzodiazepines, Z-drugs, barbiturates (all on Beers Criteria)	Fall risk, cognitive impairment, prolonged elimination
Substance use disorder	Ramelteon; melatonin; CBT-I	All scheduled agents if possible (Schedule II–IV)	Abuse potential; cross-tolerance with alcohol
Concurrent opioid use	Ramelteon; orexin antagonist	Benzodiazepines, barbiturates, Z-drugs	Boxed warning: synergistic respiratory depression
Hepatic impairment	Lorazepam, oxazepam, temazepam (LOT agents)	Diazepam, chlordiazepoxide (active metabolites accumulate)	LOT agents: glucuronidation only, no active metabolites
Pregnancy	Non-pharmacological approaches preferred	Benzodiazepines (floppy infant syndrome); barbiturates	Teratogenicity data limited; neonatal withdrawal risk

Prescribing Principles

Use the lowest effective dose for the shortest duration. All scheduled sedative-hypnotics carry dependence risk; benzodiazepines prescribed for >2–4 weeks require a taper plan at initiation.

CBT-I is first-line for chronic insomnia — more durable benefit than pharmacotherapy and without dependence or next-day impairment.

Never combine with opioids without specific documented indication — the respiratory depression risk is synergistic, not additive.

Flumazenil reversal carries more risk than benzodiazepine overdose itself in physically dependent patients — use only when you know the patient is not dependent and co-ingestion of tricyclics is ruled out.

Suggested References

Author / Organization	Title	Source
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed. Chapter 22: Sedative-Hypnotic Drugs	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. Chapter 17: Hypnotics and Sedatives	McGraw-Hill, 2023
Hobson JA	Sleep is of the brain, by the brain and for the brain	Nature. 2005;437(7063):1254–1256
Borbely AA, Daan S, Wirz-Justice A, Deboer T	The two-process model of sleep regulation: a reappraisal	J Sleep Res. 2016;25(2):131–143
Kato K, Hirai K, Nishiyama K, et al	Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist	Neuropharmacology. 2005;48(2):301–310
Sakurai T	The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness	Nat Rev Neurosci. 2007;8(3):171–181
Sanna E, Busonero F, Talani G, et al	Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA-A receptor subtypes	Eur J Pharmacol. 2002;451(2):103–110
Herring WJ, Connor KM, Ivgy-May N, et al	Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials	Biol Psychiatry. 2016;79(2):136–148
Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD	Dexmedetomidine in the care of critically ill patients from 2001 to 2007	Anesthesiology. 2010;113(2):386–394
Sateia MJ, Buysse DJ, Krystal AD, et al	Clinical practice guideline for the pharmacological treatment of chronic insomnia in adults	J Clin Sleep Med. 2017;13(2):307–349
Baldwin DS, Anderson IM, Nutt DJ, et al	Evidence-based pharmacological treatment of anxiety disorders	J Psychopharmacol. 2014;28(5):403–439
American Geriatrics Society	2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults	J Am Geriatr Soc. 2023;71(7):2052–2081